دورية أكاديمية
أعرض في EDS

NK-92 cells labeled with Fe 3 O 4 -PEG-CD56/Avastin@Ce6 nanoprobes for the targeted treatment and noninvasive therapeutic evaluation of breast cancer.

التفاصيل البيبلوغرافية
العنوان: NK-92 cells labeled with Fe 3 O 4 -PEG-CD56/Avastin@Ce6 nanoprobes for the targeted treatment and noninvasive therapeutic evaluation of breast cancer.
المؤلفون: Lian J; Department of Radiology, Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 201600, P.R. China.; Department of Radiology, Peking University Third Hospital, Beijing, 100191, China., Li M; State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Biological Science and Medical Engineering, Donghua University, Shanghai, 201620, China., Duan M; Department of Instrument Science and Technology, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China., Sun Y; Department of Radiology, Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 201600, P.R. China.; Department of Immunology, School of Cell and Gene Therapy, Songjiang Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, 201600, P.R. China., Wang Z; Department of Radiology, Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 201600, P.R. China., Guo X; Department of Radiology, Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 201600, P.R. China., Li J; State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Biological Science and Medical Engineering, Donghua University, Shanghai, 201620, China. jcli@dhu.edu.cn., Gao G; Department of Instrument Science and Technology, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China. guogao@sjtu.edu.cn., Li K; Department of Radiology, Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 201600, P.R. China. kangan.li@shsmu.edu.cn.
المصدر: Journal of nanobiotechnology [J Nanobiotechnology] 2024 Jun 05; Vol. 22 (1), pp. 313. Date of Electronic Publication: 2024 Jun 05.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155 (Electronic) Linking ISSN: 14773155 NLM ISO Abbreviation: J Nanobiotechnology Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, 2003-
مواضيع طبية MeSH: Breast Neoplasms*/therapy , Killer Cells, Natural* , Photochemotherapy*/methods , Polyethylene Glycols*/chemistry , CD56 Antigen*/metabolism, Humans ; Female ; Animals ; Mice ; Cell Line, Tumor ; Immunotherapy, Adoptive/methods ; Apoptosis/drug effects ; Magnetic Resonance Imaging/methods ; Mice, Inbred BALB C ; Mice, Nude
مستخلص: Adoptive cellular immunotherapy as a promising and alternative cancer therapy platform is critical for future clinical applications. Natural killer (NK) cells have attracted attention as an important type of innate immune regulatory cells that can rapidly kill multiple adjacent cancer cells. However, these cells are significantly less effective in treating solid tumors than in treating hematological tumors. Herein, we report the synthesis of a Fe 3 O 4 -PEG-CD56/Avastin@Ce6 nanoprobe labeled with NK-92 cells that can be used for adoptive cellular immunotherapy, photodynamic therapy and dual-modality imaging-based in vivo fate tracking. The labeled NK-92 cells specifically target the tumor cells, which increases the amount of cancer cell apoptosis in vitro. Furthermore, the in vivo results indicate that the labeled NK-92 cells can be used for tumor magnetic resonance imaging and fluorescence imaging, adoptive cellular immunotherapy, and photodynamic therapy after tail vein injection. These data show that the developed multifunctional nanostructure is a promising platform for efficient innate immunotherapy, photodynamic treatment and noninvasive therapeutic evaluation of breast cancer.
(© 2024. The Author(s).)
References: Small. 2024 Feb;20(8):e2306378. (PMID: 37817359)
Angew Chem Int Ed Engl. 2024 Jan 8;63(2):e202310252. (PMID: 38010197)
Nat Nanotechnol. 2021 Jan;16(1):25-36. (PMID: 33437036)
Sci Adv. 2022 Mar 25;8(12):eabh4050. (PMID: 35319989)
Adv Mater. 2021 Jun;33(23):e1906539. (PMID: 32495404)
CA Cancer J Clin. 2019 Nov;69(6):438-451. (PMID: 31577379)
Front Oncol. 2019 Dec 19;9:1448. (PMID: 31921693)
Front Bioeng Biotechnol. 2023 Jul 19;11:1248283. (PMID: 37539436)
Biomaterials. 2018 Jul;170:1-11. (PMID: 29635107)
Nat Rev Cancer. 2020 Aug;20(8):417-436. (PMID: 32528185)
Nanoscale. 2019 Oct 10;11(39):18426-18435. (PMID: 31576881)
Blood Cancer J. 2021 Apr 6;11(4):69. (PMID: 33824268)
Theranostics. 2017 Jan 25;7(3):764-774. (PMID: 28255365)
J Hematol Oncol. 2022 Aug 29;15(1):121. (PMID: 36038913)
Mol Cancer. 2023 Feb 7;22(1):28. (PMID: 36750830)
Acta Biomater. 2022 Sep 01;149:334-346. (PMID: 35779775)
Immunol Rev. 2014 Jan;257(1):107-26. (PMID: 24329793)
Lancet. 2017 Oct 7;390(10103):1654-1663. (PMID: 28756902)
Biomater Res. 2022 Jun 11;26(1):23. (PMID: 35690811)
J Colloid Interface Sci. 2022 Aug;619:219-228. (PMID: 35397457)
N Engl J Med. 2006 May 18;354(20):2103-11. (PMID: 16707747)
Front Immunol. 2022 Jun 10;13:927153. (PMID: 35757715)
Biomaterials. 2019 Oct;217:119309. (PMID: 31271855)
J Control Release. 2018 Jan 28;270:237-245. (PMID: 29247665)
Nat Rev Cancer. 2022 Oct;22(10):557-575. (PMID: 35879429)
Int J Biol Macromol. 2022 May 31;208:669-677. (PMID: 35346676)
Nanoscale. 2021 Nov 25;13(45):19109-19122. (PMID: 34766615)
Leukemia. 2020 May;34(5):1291-1304. (PMID: 31772298)
Cancer Treat Rev. 2020 Jun;86:102017. (PMID: 32335505)
Nano Lett. 2016 Apr 13;16(4):2512-21. (PMID: 27022664)
Cancer Immunol Res. 2018 Oct;6(10):1174-1185. (PMID: 30018043)
ACS Appl Mater Interfaces. 2019 Nov 13;11(45):41829-41841. (PMID: 31617343)
Cell Rep. 2021 Aug 31;36(9):109632. (PMID: 34469729)
Adv Mater. 2016 Oct;28(40):8912-8920. (PMID: 27558441)
Cell Mol Immunol. 2019 May;16(5):415-422. (PMID: 30911118)
J Mater Chem B. 2023 Sep 13;11(35):8484-8491. (PMID: 37593820)
Small. 2023 Jan;19(1):e2205440. (PMID: 36285777)
Adv Mater. 2023 Aug;35(33):e2302508. (PMID: 37165741)
J Natl Cancer Inst. 2017 Nov 1;109(11):. (PMID: 29059426)
Dalton Trans. 2018 Mar 12;47(11):3931-3939. (PMID: 29459928)
Science. 2015 Apr 3;348(6230):62-8. (PMID: 25838374)
Theranostics. 2022 Jan 1;12(1):434-458. (PMID: 34987658)
Angew Chem Int Ed Engl. 2020 Jul 13;59(29):12022-12028. (PMID: 32246555)
ACS Appl Mater Interfaces. 2021 Nov 24;13(46):54830-54839. (PMID: 34767354)
معلومات مُعتمدة: GG 81671737 National Natural Science Foundation of China; KAL 12090024 National Natural Science Foundation of China; GG18PJD020 Shanghai Pujiang Project; KAL 2014PJD028 Shanghai Pujiang Project
فهرسة مساهمة: Keywords: Adoptive cellular immunotherapy; Magnetic resonance imaging; Multimodal nanomaterials; NK-92 cells; Photodynamic therapy
المشرفين على المادة: 3WJQ0SDW1A (Polyethylene Glycols)
0 (CD56 Antigen)
تواريخ الأحداث: Date Created: 20240605 Date Completed: 20240606 Latest Revision: 20240613
رمز التحديث: 20240613
مُعرف محوري في PubMed: PMC11151526
DOI: 10.1186/s12951-024-02599-x
PMID: 38840120
قاعدة البيانات: MEDLINE
الوصف
تدمد:1477-3155
DOI:10.1186/s12951-024-02599-x